Document is current
Any future updates will be listed below
-
Authors
Huo, Yanying https://orcid.org/0000-0003-4747-4951
Selenica, Pier
Mahdi, Amar H.
Pareja, Fresia https://orcid.org/0000-0003-3748-8049
Kyker-Snowman, Kelly
Chen, Ying https://orcid.org/0000-0002-0072-1567
Kumar, Rahul https://orcid.org/0000-0002-6927-5390
Da Cruz Paula, Arnaud
Basili, Thais https://orcid.org/0000-0003-3216-3544
Brown, David N.
Pei, Xin https://orcid.org/0000-0001-9961-6152
Riaz, Nadeem https://orcid.org/0000-0001-9873-5862
Tan, Yongmei
Huang, Yu-Xiu
Li, Tao
Barnard, Nicola J.
Reis-Filho, Jorge S. https://orcid.org/0000-0003-2969-3173
Weigelt, Britta https://orcid.org/0000-0001-9927-1270
Xia, Bing https://orcid.org/0000-0003-3259-6139
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA138804, R01CA188094)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Breast Cancer Research Foundation
- License Information
-
More Information
Article History
Received: 24 April 2020
Accepted: 24 March 2021
First Online: 23 April 2021
Competing interests
: N.R. reports research support/grants from Pfizer, BMS, and REPARE Therapeutics as well as honoraria from REPARE Therapeutics and Illumina, outside the scope of this study. J.S.R.-F. reports receiving personal/consultancy fees and is a member of the scientific advisory board of REPARE Therapeutics. J.S.R.-F. also declares receiving personal/consultancy fees from Goldman Sachs and Paige, membership of the scientific advisory boards of VolitionRx and Page.AI, membership of the Board of Directors of Grupo Oncoclinicas, and ad hoc membership of the scientific advisory boards of Roche Tissue Diagnostics, Ventana Medical Systems, Novartis, Genentech and InVicro, all outside the scope of this study. B.W. reports ad hoc membership of the scientific advisory board of REPARE Therapeutics, outside the scope of the submitted work. The remaining authors have no conflicts of interest to declare.
